A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

NCT ID: NCT00535522

Last Updated: 2011-12-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-08-31
• Study Completion Date: 2011-06-30

Brief Summary

The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.

Conditions

Cancer

Keywords

Pharmacokinetics; pharmacodynamics; maximal tolerated dose

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TAK-285

Group Type: EXPERIMENTAL

TAK-285 Dose Escalation Cohorts

Intervention Type: DRUG

TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).

TAK-285 Recommended Phase 2 Dosing Cohort

Intervention Type: DRUG

Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.

Interventions

TAK-285 Dose Escalation Cohorts

TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).

Intervention Type: DRUG

TAK-285 Recommended Phase 2 Dosing Cohort

Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The subject has a histologically confirmed advanced non-hematologic malignancy.
• The subject has a chemotherapy-free interval of at least 4 weeks prior to first dose of study drug.
• The subject is intolerant of, is not a candidate for, or the subject's disease is refractory to established therapy known to provide clinical benefit for their disease.
• A female subject of childbearing potential who is sexually active agrees to use adequate contraception from Screening throughout the duration of the study, and for 30 days after the last dose of study drug. Male subjects should agree to use contraception for the duration of the study, and for 30 days after the last dose of study drug.
• The subject has a life expectancy of greater than 12 weeks.
• The subject has an Eastern Cooperative Oncology Group performance status of 0 to 2.
• The subject has the ability to swallow and retain oral medication
• The subject's most recent test values within 2 weeks before the date of entry meet the following standards:

• Bone marrow function:

• Absolute neutrophil count ≥1500/mm3
• Hemoglobin ≥9.0g/dL, platelet count ≥100,000/mm3.
• Liver function:

• Total bilirubin ≤1.5 times the upper limit of the standard value of each institution
• Aspartate aminotransferase and alanine aminotransferase ≤2.5 times the upper limit of the standard value of each institution.
• Renal function:

• Serum creatinine ≤1.5 times the upper limit of the standard value of each institution.
• In the recommended phase 2 dose Cohort, the subject has an accessible tumor for biopsy and is willing to undergo 2 tumor biopsies.
• In the recommended phase 2 dose Cohort, the subject has at least 1 measurable lesion based on the treatment assessment standards for solid tumors.
• In the recommended phase 2 dose Cohort, the subject has a tumor that expresses EGFR and/or overexpresses erbB2.

Exclusion Criteria

• The subject has a symptomatic brain metastasis.
• The subject has an uncontrollable pleural effusion, ascitic fluid, or pericardial effusion.
• The subject has active gastrointestinal bleeding as evidenced by either hematemesis or melena.
• The subject has acute gastrointestinal ulcers.
• The subject has been treated with a small molecule inhibitor of EGFR or HER2 (except for lapatinib).
• The subject has a history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years.
• The subject has significant cardiovascular impairment (history of New York Heart Association class III or IV) or a history of myocardial infarction or unstable angina within the past 6 months prior to study drug treatment.
• The subject has a severe disease (other than cancer) that will likely affect the prospects of survival or a history that will make it difficult to appropriately manage and follow his or her progress in accordance with the protocol (serious organ disorder, mental illness, drug abuse, alcohol dependency, etc.).
• The subject requires prohibited treatment (drug, surgery or radiotherapy for treatment of malignant tumor, drugs that could interact with TAK-285) except for radiotherapy of limited area (<20% of total bone marrow) in order to relieve the symptoms from symptomatic bone metastasis.
• The subject who has been treated with a drug, which inhibits or induces Cytochrome P450 3A4 within 1 week prior to the start of treatment with the investigational drug.
• The subject is pregnant or breast feeding.
• The subject has participated in another clinical study/postmarketing clinical study within 4 weeks prior to the start of treatment with TAK-285.
• The subject is currently taking excluded medications, including:

• Concurrent anticancer therapy with agents other than TAK-285.
• The following prohibited medications and substances should not be used for at least 7 days prior to the start of the study and throughout completion:

• Strong CYP3A4 inhibitors

• Amiodarone
• Diltiazem
• Verapamil
• Human immunodeficiency virus protease inhibitors
• itraconazole
• ketoconazole
• macrolide antibiotics (excluding azithromycin)
• Strong CYP3A4 inducers

• Carbamazepine
• Efavirenz
• Nevirapine
• Phenytoin
• Rifabutin
• Rifampin.
• St. John's wort
• Medications and devices containing hormones such as oral contraceptives.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Millennium Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Millennium Pharmaceuticals, Inc.

Locations

Indiana University Cancer Center

Indianapolis, Indiana, United States

University of Maryland Greenbaum Cancer Center

Baltimore, Maryland, United States

Karmanos Cancer Center

Detroit, Michigan, United States

Countries

United States

References

LoRusso P, Venkatakrishnan K, Chiorean EG, Noe D, Wu JT, Sankoh S, Corvez M, Sausville EA. Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Invest New Drugs. 2014 Feb;32(1):160-70. doi: 10.1007/s10637-013-9988-x. Epub 2013 Jul 2.

Reference Type: DERIVED

PMID: 23817974 (View on PubMed)

Other Identifiers

TAK-285_101

Identifier Type: -

Identifier Source: org_study_id